Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
NCT Number: NCT07297225
Near-infrared fluorescence cholangiography has been shown to improve the clinical outcomes of laparoscopic cholecystectomy (LC). However, it remains unclear whether hepatic steatosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) influences the quality of indocyanine green fluorescence imaging (ICG-FI), and whether the quality can be predicted preoperatively. This study aimed to evaluate the impact of MAFLD on intraoperative fluorescence quality and to develop a multiple linear regression model for predicting intraoperative ICG-FI.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Guangzhou, Guangdong, 510280, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(4) Incomplete clinical data.
Retrospective observational study without intervention measures
Time frame: Perioperative period
The common bile duct-to-liver background fluorescence intensity ratio (C/L) [Unit: Dimensionless number] [Time Frame: Perioperative period] [Measurement steps: Three photographs per case were obtained with the following requirements: Calot's triangle centred in the image, liver background positioned superiorly, and the CBD inferiorly, ensuring all measurement sites were visible and unobstructed. Each image was converted to greyscale, and regions of interest (ROI) of >3000 pixels were selected for each critical structure to calculate FI. The mean FI from the three images was recorded as the final value for each structure.]
Time frame: Perioperative period
Qualitative assessment of fluorescence visualization. [Time Frame: Perioperative period] [Unit: Dimensionless number] [Measurement steps: It was performed by three senior surgeonsScores were averaged and graded on a five-point scale adapted from previous studies (1=completely invisible, impairs visualization; 2=poor, faint fluorescence, no added value; 3= visible but blurred, some added value; 4=good, clear visualization with significant added value; 5= excellent, very clear visualization with typical added value)]
Time frame: Perioperative period
HSI(Hepatic Steatosis Index) and FSI (Framingham Steatosis Index) [Time Frame: Perioperative period] [Unit: Dimensionless number] [The variables included:ALT and AST(IU/L), BMI(kg/m2), gender(male/female), diabete(yes/no), age(years), TG (mmol/L), Hypertension(yes/no)]
Zhujiang Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06940375
Digestive System Diseases, Fatty Liver
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07305636
AI (Artificial Intelligence), MAFLD
Tanta, Egypt
View Trial DetailsNCT07679542
MAFLD
Nanjing, Jiangsu, China
View Trial DetailsNCT07564947
Digestive System Diseases, Fatty Liver
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial Details